Lexeo Raises $100m To Advance CNS Candidates, Validate Cardiac Gene Therapies
Start-Up Has Brought In $185m In Less Than A Year
The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.
